Posts

AstraZeneca's Tozorakimab Achieves Phase 3 Success in Broader COPD Population

on

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

on

Sanofi, Regeneron's IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

on

Sanofi, Regeneron's IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

on